



RED BLOOD CELL ACETYLCHOLINESTERASE AND 
PLASMA BUTYRYLCHOLINESTERASE STATUS: 
IMPORTANT INDICATORS FOR THE TREATMENT OF 
PATIENTS POISONED BY ORGANOPHOSPHORUS 
COMPOUNDS*
Horst THIERMANN1, Kai KEHE1, Dirk STEINRITZ1, John MIKLER2, Ira HILL2,
Thomas ZILKER3, Peter EYER4, and Franz WOREK1
Bundeswehr Institute of Pharmacology and Toxicology, Munich, Germany1, Casualty 
Management Section, Defence Research and Development, Suffield, Canada2, Toxicological 
Departments, 2nd Medical Clinic, Technical University, Munich, Germany3,
Walther-Straub-Institute of Pharmacology and Toxicology, Munich, Germany4
Received in August 2007
Accepted in September 2007
Inhibition of acetylcholinesterase (AChE) is regarded as the primary toxic mechanism of organophosphorus 
compounds (OP). Therapeutic strategies are directed to antagonise overstimulation of muscarinic receptors 
with atropine and to reactivate inhibited AChE with oximes. Reactivation is crucial within the neuromuscular 
synapse, where atropine is ineffective, since peripheral neuromuscular block eventually leads to respiratory 
failure. Patients with OP intoxication have to be identified as early as possible.
During an international NBC-defence exercise anesthetised pigs were poisoned with sarin, followed by 
treatment with atropine and oxime. Blood samples were drawn and red blood cell (RBC)-AChE activity 
determined with a fielded test system on-site. Within a few minutes the poisoning was verified. After 
administration of HI-6, RBC-AChE activity increased rapidly. Blood samples were reanalysed in our 
laboratory in Munich. Almost identical course of the AChE activities was recorded by both systems.
The more comprehensive cholinesterase status was determined in Munich. Oxime administration can be 
stopped when AChE is aged completely, but has to be continued as long as poison is present in the body 
and reactivation is possible. 
To aid the on-site physician in optimising diagnosis and treatment, a fielded test system should be available 
to allow rapid determination of the complete cholinesterase status.
KEY WORDS: human poisoning, nerve agents, neuromuscular transmission, oxime therapy, 
pesticides
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Organophosphorus compounds are widely 
used for pest control in agriculture. Poisoning is 
frequent, especially in developing countries, due 
to suicide attempts and accidents with more than 
200,000 deaths per year worldwide. Among the 
organophosphorus compounds, nerve agents are a 
subgroup with high toxicity for humans. The terrorist 
use of Sarin and VX in Japan (1) has shown the world 
that nerve agents are no longer restricted to chemical 
battlefields, but are a pertinent threat for civilian 
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and military populations. Consequently, effective 
therapeutic preparedness is mandatory. Inhibition of 
acetylcholinesterase (AChE, EC 3.1.1.7) is regarded 
as the primary mechanism for the acute toxicity of all 
organophosphorus compounds (OP), nerve agents 
as well as pesticide OP, and therefore should be an 
integral part of casualty diagnosis and treatment. 
Therapeutic strategies are directed to competitively 
antagonise overstimulation of muscarinic receptors 
by antimuscarinics such as atropine, and to reverse 
AChE inhibition by reactivation with oximes, e.g. 
pralidoxime or obidoxime. The latter approach is 
crucial within neuromuscular synapses where atropine 
fails, since peripheral neuromuscular block eventually 
leads to respiratory failure. A lot of research has been 
performed over the last several decades, leading 
to a better understanding of individual reactions 
during and after inhibition [aging, spontaneous 
reactivation, oxime induced reactivation, formation 
of phosphoryloximes and their interactions; for review 
see (2)]. It can be concluded that all of these reactions 
must be considered for the optimal treatment of 
poisoned patients.
DEVELOPMENT OF AN OPTIMAL TREATMENT 
REGIMEN
Treatment of signs and symptoms due to 
overstimulation of muscarinic receptors
Typical signs and symptoms of cholinergic 
crisis develop in direct correlation with the degree 
of acetylcholinesterase inhibition (3). In severe 
poisoning, respiratory depression, bronchospasm, 
bronchosecretion and weakness of the respiratory 
muscles call for immediate endotracheal suctioning 
and artificial ventilation. Generally, treatment with 
muscarinic receptor antagonists, e.g. atropine should 
achieve heart rate between 80 and 100 beats per 
minute, the absence of rales during auscultation, 
and skin dryness (axilla). Furthermore, frequent 
circulatory insufficiency may call for treatment with 
catecholamines to increase and maintain blood 
pressure (i.e. arterial mean pressure above 60 mm Hg 
with systolic pressure exceeding 100 mm Hg) as well 
as heart rate. In the later phase of severe poisoning, 
rales might be the result of cardiac insufficiency or 
(aspiration) pneumonia accompanied by elevated 
temperature and sweating, thus preventing the use 
of these parameters as clear indicators of atropine 
demand. In conclusion, in the acute phase of 
poisoning, atropine dosing should follow a protocol 
guaranteeing an early sufficient atropinisation. Such 
protocols are proposed in modern literature (4, 5), 
recommending a starting dose of 2 mg i.v. followed 
by an observation period of 5 min. If there is no 
effect, this dose may be doubled every 5 min to10 
min until muscarinic symptoms subside. With the 
5th dose in this regimen, 62 mg of atropine would be 
administered, an amount that should suffice. For the 
ongoing treatment, especially at intensive care units, 
the whole clinical picture has to be considered and 
dosing of atropine should be performed with caution 
(e.g. 1 mg h-1 to 4 mg h-1) to avoid adverse effects.
Reactivation of acetylcholinesterase
As atropine is not able to counteract signs and 
symptoms caused by the overstimulation of nicotinic 
receptors, especially at neuromuscular endplates, 
the concept of reactivation of inhibited AChE was 
developed (6), and pralidoxime (7) and obidoxime (8) 
were introduced into clinical therapy fifty years ago. 
Since the sixties, textbooks recommend 4 µg mL-1
of oxime as the effective therapeutic concentration. 
This recommendation is based on a study in cats 
poisoned by a sarin analogue and then treated 
with pralidoxime. The result from this investigation 
“... plasma concentrations of about 2x10-5 mol L-1
(4 µg mL-1) were needed to counteract neuromuscular 
block, bradycardia, hypotension and respiratory failure 
...” (9) was extrapolated without critical evaluation for 
treatment of any OP-type-poisoning, using any oxime, 
and in any species. However, various OPs show quite 
different properties in reacting with AChE (10) and 
reactivation depends both on the properties of the 
OP-AChE conjugates and of the oxime used (2, 11). 
Moreover, enormous differences between species have 
to be considered (12). Based on reaction constants 
derived from experiments with human RBC-AChE, 
reasonable plasma concentrations of oximes for 
reactivation of insecticide as well as nerve agent-
inhibited AChE can be calculated (2, 11, 13-19). 
Results indicate that AChE inhibited by most nerve 
agents and insecticide OPs can be reactivated with 
obidoxime at a plasma concentration of approximately 
10 µmol L-1. This plasma concentration can be 
adjusted by an i.v. bolus dose of 250 mg, followed by 
750 mg of obidoxime per day. In actual emergency 
situations, this regimen proved effective in reactivating 
AChE inhibited by insecticide OP (11, 16, 20). 
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Comparably, Pawar (21) showed reduced morbidity 
and mortality in moderately severe insecticide OP-
poisoned patients treated with effective doses of 
pralidoxime (2 g loading dose, followed by 24 g per 
day). Hence, effective oximes should be administered 
in appropriate dosage as early as possible (e.g. by 
autoinjectors or i.v.) and effective concentrations 
should be maintained as long as reactivation is 
possible. The treatment period may be shortened 
to several hours in poisoning with OP where toxic 
concentrations persist only for a very short time in the 
body (e.g. sarin) or when OP-AChE-conjugates age 
quickly (e.g. soman). In contrast, in poisoning with 
persisting nerve agents (e.g. VX) or after ingestion of 
huge amounts of poison as frequently found in suicide 
poisoning, administration of oximes may be necessary 
for several days.
MONITORING OF THE CHOLINESTERASE 
STATUS
Assessment of therapeutic effectiveness in OP-
poisoned patients is difficult due to a wide variety of 
therapeutic measures taken at intensive care units 
(e.g. artificial ventilation, sedation). To monitor the 
course of poisoning in OP-poisoned patients, a 
laboratory test system, called cholinesterase status,
was developed (16, 22) and used in intensive care 
units (Figure 1) (11, 20, 23, 24). The cholinesterase 
status consisted of: 
· Red blood cell (RBC)-AChE activity: Blood 
was immediately diluted bed-side 1:100 (v/v) 
with ice-cold phosphate-buffer (0.1 mol L-1, pH 
7.4; 0.03 % Triton X-100). AChE activity was 
determined according to a modified Ellman 
method (22). Reactivatability of RBC-AChE 
activity was assessed by incubation of diluted 
blood samples with 0.1 mmol L-1 obidoxime at 
37 °C for 30 min (22). 
· Inhibitory material, indicating the presence 
of active poison in the body without its exact 
identification: Plasma of patients was incubated 
with standardized RBC-AChE obtained from a 
healthy donor at 37 °C for 1 h. Thereafter the 
RBC-AChE activity was measured according 
to the modified Ellman method (22). Plasma 
butyrylcholinesterase (BChE; EC 3.1.1.8) activity 
was determined by the Ellman method with 
some minor modifications using 1.0 mmol L-1
butyrylthiocholine as substrate (22).
Determination of the cholinesterase status is 
possible in our laboratory by using an automated 
Figure 1 Cholinesterase status of a patient with parathion poisoning. 
Obidoxime plasma concentration was determined by HPLC 
according to Spoehrer at al. (46) (upper panel, A). RBC-AChE 
activity (mid panel B; triangles, full line) and reactivatability 
(mid panel B; squares, hatched line) were determined 
according to a modified Ellman method. Inhibitory activity (%) 
was estimated as AChE activity of donor RBCs incubated with 
the patient’s plasma (lower panel, C; open squares, hatched 
line); and paraoxon (nmol L-1) calculated from RBC-AChE 
activity, reactivatability and obidoxime plasma concentration 
using the respective reaction constants (lower panel, C; open 
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system with a capacity to perform 600 assays per 
day (25, 26). Furthermore, for determination of RBC-
AChE and plasma BChE an improved portable device, 
appropriate for the use in the field was developed 
(27).
To demonstrate the properties of cholinesterase 
status, a case report of parathion poisoning is 
presented here [compare (28, 29)]. This example 
resembles a course of poisoning that might be 
expected in percutaneous intoxication with a persisting 
OP such as VX. A 45-year-old man ingested about 
100 mL of a parathion-containing solution. On 
presentation to the emergency physician, the patient 
was unconscious with severe signs and symptoms 
of cholinergic crisis. After administration of 1.5 mg 
of atropine the patient was intubated and artificial 
ventilation was initiated. At the local hospital gastric 
lavage was performed and the patient was stabilized. 
After treatment with 2 bolus doses of obidoxime and 
atropine infusion, the patient was transferred to the 
intensive care unit of the toxicological department of 
the 2nd Medical Clinic, Technical University, Munich. 
Here, the obidoxime regimen was started (250 mg 
i.v. bolus, followed by 750 mg per day), maintaining 
the therapeutic plasma level of about 10 µmol L-1
obidoxime (Figure 1, A, upper panel). Due to the 
persisting poison load, only partial reactivation of RBC-
AChE could be achieved over approximately four days. 
During this period, very little aging occurred (Figure 
1, B, mid panel) and BChE remained completely 
inhibited. When the poison load significantly 
decreased on the fourth day following initiation of the 
obidoxime regimen, complete AChE reactivation was 
achieved. Furthermore, based on RBC-AChE activity, 
reactivatability and obidoxime plasma concentration, 
a paraoxon concentration necessary for such a degree 
of inhibition could be calculated (29) by using the 
respective reaction constants (17). The time course of 
this theoretical curve closely fits the actual time course 
of inhibitory activity, as determined in the poisoned 
patient (Figure 1, C, lower panel).
In cases of exposure to nerve agents, early 
determination of RBC-AChE is mandatory to confirm 
clinical diagnosis without sophisticated verification 
of the agent used. For this purpose, the Test 
Mate® was developed by EQM research (27). The 
device was tested in an international NBC-defence 
exercise (Precise Response 2006, Canada). During 
the training scenario, the diagnostic group of the 
German Medical-Chemical Task Force entered a 
chemical agent environment for treatment of victims 
of a terrorist attack. An anesthetized pig poisoned 
with sarin emulated a poisoned patient. On arrival, 
the pig (∼20 kg) displayed typical clinical signs of 
cholinergic crisis; salivation, miosis and dyspnoea. 
Using the Test-Mate® system marked inhibition of 
AChE verified poisoning with a cholinesterase inhibitor 
within a few minutes. After administration of the oxime 
HI-6 (260 mg) in combination with atropine (0.6 mg) 
(bolus dose), a rapid increase in RBC-AChE activity 
was recorded on site. This was clearly accompanied 
by prompt clinical improvement, indicating the 
effectiveness of the oxime treatment. To simulate the 
situation following rescue and decontamination, two 
additional pigs were poisoned with sarin and treated 
at a field intensive care unit. Here, HI-6 or obidoxime 
were administered in combination with atropine. As 
observed in the field, the clinical situation improved 
after oxime treatment, however repetitive atropine 
doses were necessary to counteract hypersalivation. 
In one pig, diazepam was also required due to 
convulsions. These animals were maintained under 
anaesthetic for approximately two hours, during which 
time their blood was sampled. RBC-AChE activity as 
well as plasma BChE activity were determined on site 
to monitor the course of treatment. In addition, blood 
samples were sent to our laboratory in Munich and 
were reanalysed with an automated analysis system 
(Tecan RMP). Comparison of the results showed 
almost identical values independent of the analytic 
system used (Figure 2, upper panel).
INVESTIGATION OF NEUROMUSCULAR 
TRANSMISSION
Investigations on muscle strips of various species 
revealed that oximes were able to restore force 
to muscles paralysed by OP; however, several 
therapeutic gaps (e.g. soman) still exist (30-36). 
Aside from an unknown direct oxime reaction, 
recovery of muscle force was mainly attributed 
to the reactivation of inhibited muscle AChE. A 
series of experiments on phrenic nerve-diaphragm-
preparations of mice circumfused with paraoxon 
showed that obidoxime restored muscle force, and 
this was clearly accompanied by an increase in 
muscle AChE activity (36). Comparably, in patients 
with insecticide OP-poisoning, it was reported that 
low RBC-AChE activity (<10 %) was associated with 
marked decrement-phenomena (23) (stimulation 
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of a nerve with frequencies of 30 Hz to 50 Hz and 
recording of compound action potentials), indicating 
severe disturbance of neuromuscular transmission 
and urgent requirement of artificial ventilation (37, 
38). At RBC-AChE activity of about 15 % to 20 % 
mainly decrement-increment-phenomena occurred 
(23). This type of response is typically found in 
moderate to severe poisoning (37, 38), presumably 
also indicating the need for artificial ventilation. At 
RBC-AChE activity above 30 %, little disturbance of 
neuromuscular transmission could be detected (23). 
AChE is encoded on a single gene in mammalian 
species (39), and therefore a similar structure may be 
assumed to occur throughout the body (2, 40, 41). 
Consequently, RBC-AChE should have comparable 
functional properties to synaptic AChE and therefore 
may be used as surrogate parameter, reflecting the 
AChE status at the synaptic site. However, when 
RBC-AChE ages completely, restoration takes several 
months (42) while synaptic AChE recovers faster (43, 
44). Therefore, under these conditions, RBC-AChE 
can no longer be regarded as a suitable parameter to 
indicate the end of the cholinergic crisis. As BChE may 
show quite different properties concerning inhibition 
by OPs as well as reactivation of the inhibited enzyme 
by oximes (2, 45), this parameter has to be used 
Figure 2 Cholinesterase activity, reactivatability and inhibitory material determined in pig blood samples following sarin exposure. During the 
NBC-defence exercise Precise Response 2006 in Canada, anaesthetized pigs were poisoned with sarin and treated with HI-6 or obidoxime.
After the poisoning, (A) RBC-AChE was determined on-site with the Test Mate® system and then with an automated system (Tecan) at
the Bundeswehr Institute of Pharmacology and Toxicology in Munich. Additionally, (B) BChE in plasma (mU/ml), (C) reactivatability of 
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with caution. Under such conditions, investigation 
of neuromuscular transmission may be of help. 
Especially when ventilators are in limited supply, e.g. 
mass casualties with rapidly aging OP, investigation 
of neuromuscular transmission could guide the 
physician whether artificial ventilation is necessary.
RECOMMENDATION FOR DIAGNOSIS AND 
TREATMENT OF PATIENTS POISONED BY 
ORGNOPHSPHORUS COMPOUNDS
RBC-AChE activity should be determined as early 
as possible to confirm the diagnosis of poisoning by 
inhibitors of cholinesterase.
Atropine should be given according to clinical 
signs and symptoms using a regime which ensures 
fast atropinisation without overdosing, e.g. doubling 
the doses every 5 min after a starting dose with 
2 mg.
Effective oximes should be administered at 
appropriate doses as early as possible to OP-poisoned 
patients.
The effects of oximes may be assessed using 
the cholinesterase status, thus allowing optimal 
oxime treatment; oximes should be administered 
as long as reactivation is possible and inhibitory 
material is present in the patient. Investigation of the 
neuromuscular transmission should complete the 
monitoring system as objective clinical parameter. 
Especially when RBC-AChE activity ages completely, 
improvement of neuromuscular transmission may 
be the decisive parameter to indicate the end of the 
cholinergic crisis. This item urgently needs further 
investigation.
To aid the on-site physician in optimizing diagnosis 
and treatment, field test systems should be further 
advanced to allow for rapid determination of the 
extended cholinesterase status.
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Sa`etak
ACETILKOLINESTERAZA U ERITROCITIMA I BUTIRILKOLINESTERAZA U PLAZMI – VA@NI POKAZATELJI 
ZA LIJE^ENJE OSOBA OTROVANIH ORGANOFOSFORNIM SPOJEVIMA
Inhibicija acetilkolinesteraze (AChE) smatra se primarnim mehanizmom toksi~noga djelovanja 
organofosfornih spojeva (OP). Strategije lije~enja idu za zaustavljanjem prekomjerne stimulacije 
muskarinskih receptora atropinom i reaktiviranjem inhibiranog AChE oksimima. Klju~na je reaktivacija u 
neuromuskularnoj sinapsi, u kojoj atropin nije djelotvoran, budu}i da neuromuskularna blokada u kona~nici 
vodi do prestanka disanja. Va`no je {to ranije prepoznati otrovanje organofosfornim spojem.
U jednoj me|unarodnoj vje`bi za{tite od nuklearnog, biolo{kog i kemijskog napada svinje pod anestezijom 
otrovane su sarinom te lije~ene atropinom i oksimom. Uzeti su im uzorci krvi te s pomo}u terenskoga testa 
na licu mjesta odre|ena aktivnost AChE u eritrocitima. Otrovanje je potvr|eno za nekoliko minuta. Nakon 
primjene HI-6, aktivnost AChE brzo je porasla. Isti su uzorci krvi ponovno analizirani u na{em laboratoriju 
u Münchenu. Oba su testa zabilje`ila gotovo istovjetan tijek aktivnosti AChE. U Münchenu je me|utim 
napravljen potpuniji nalaz kolinesteraza. Lije~enje oksimima mo`e se prekinuti kada AChE potpuno “ostari” 
(tj. dealkilira), ali ga valja nastaviti dokle god je otrov u tijelu, a reaktivacija mogu}a.
Lije~nici na terenu trebali bi raspolagati terenskim testovima radi brzoga i potpunog utvr|ivanja statusa 
kolinesteraza, a time i kvalitetnije dijagnoze.
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